ArticleJournal of hepatology2024
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
Article in Journal of hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Ultrasound-Based Skeletal Muscle Assessment for Prognostication in Cirrhosis: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Systematic review of prognostic value of cardiorespiratory fitness in patients with cirrhosis.BMC gastroenterology · 2026Pooled it
- The impact of sarcopenia and frailty on decompensation in compensated cirrhosis: A systematic review.Hepatology communications · 2025Pooled it
- Myosteatosis and the clinical outcomes of patients with liver cirrhosis: A meta-analysis.PloS one · 2024Pooled it
- Sarcopenia and Skeletal Muscle Dysfunction in Liver Cirrhosis: Clinical Perspectives of Myostatin Inhibition.Biomedicines · 2026Review
- Myosteatosis is associated with adverse in-hospital outcomes and CONUT score in hospitalized internal medicine patients.Acta diabetologica · 2026Article
- The dynamic spectrum of steatotic liver disease: the global perspective.Nature reviews. Gastroenterology & hepatology · 2026Review
- Prognostic value of CT-derived body composition phenotypes for patients undergoing resection of hepatocellular carcinoma: a multicenter study.Abdominal radiology (New York) · 2026Article
- Sarcopenia Is Associated With Mortality and Progression of Cirrhosis in Decompensated but Not Compensated Disease-A Multicentre Study.Alimentary pharmacology & therapeutics · 2026Article
- Sarcopenia Predicts Mortality and Hepatic Encephalopathy After TIPS in Older Adults With Cirrhosis and Improves Prognostic Scores.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Association of CT-derived muscle quality with multiple geriatric syndromes in older adults: a cross-sectional study.GeroScience · 2026Article
- Assessment of sarcopenia in cirrhosis: A practical approach using thigh and psoas ultrasound, bioimpedance, and anthropometry.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026Article
- Low muscle mass predicts liver-related outcomes in cirrhosis, independent of portal hypertension: A retrospective cohort study.Canadian liver journal · 2026Article
- Bidirectional Regulation between Metabolic Dysfunction-associated Steatotic Liver Disease and Sarcopenia via Liver-muscle Crosstalk.Journal of clinical and translational hepatology · 2026Article
- Correlation between sarcopenia and esophageal stenosis following endoscopic submucosal dissection and construction of a postoperative stenosis risk model.World journal of gastroenterology · 2026Article
- Intramuscular Fat as a Biomarker of Muscle Health: Strengths, Limitations and Open Challenges.Journal of cachexia, sarcopenia and muscle · 2026Review
- Preoperative systemic inflammation and muscle fatty infiltration are prognostic factors for quadriceps atrophy following anterior cruciate ligament reconstruction.Frontiers in immunology · 2026Article
- Visceral to subcutaneous fat area ratio as a novel prognostic biomarker in cirrhosis patients undergoing TIPS: a retrospective study.Frontiers in medicine · 2026Article
- Myosteatosis: Epidemiological Insights, Functional Decline, and Diagnostic Advances.Current obesity reports · 2025Review
- Mortality Prediction by Bedside Rectus Femoris Muscle Ultrasound for Sarcopenia Diagnosis in Liver Cirrhosis.United European gastroenterology journal · 2025Article
Corrections and comments
- Commented on by
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsSarcopenia and myosteatosis are common in patients with cirrhosis. This study aimed to determine the prevalence of these muscle changes, their interrelations and their prognostic impact over a 12-month period.
methodsWe conducted a prospective multicentre study involving 433 patients. Sarcopenia and myosteatosis were evaluated using computed tomography scans. The 1-year cumulative incidence of relevant events was assessed by competing risk analysis. We used a Fine-Gray model adjusted for known prognostic factors to evaluate the impact of sarcopenia and myosteatosis on mortality, hospitalization, and liver decompensation.
resultsAt enrolment, 166 patients presented with isolated myosteatosis, 36 with isolated sarcopenia, 135 with combined sarcopenia and myosteatosis and 96 patients showed no muscle changes. The 1-year cumulative incidence of death in patients with either sarcopenia and myosteatosis (13.8%) or isolated myosteatosis (13.4%) was over twice that of patients without muscle changes (5.2%) or with isolated sarcopenia (5.6%). The adjusted sub-hazard ratio for death in patients with muscle changes was 1.36 (95% CI 0.99-1.86, p = 0.058). The cumulative incidence of hospitalization was significantly higher in patients with combined sarcopenia and myosteatosis than in patients without muscle changes (adjusted sub-hazard ratio 1.18, 95% CI 1.04-1.35). The cumulative incidence of liver decompensation was greater in patients with combined sarcopenia and myosteatosis (p = 0.018) and those with isolated sarcopenia (p = 0.046) than in patients without muscle changes. Lastly, we found a strong correlation of function tests and frailty scores with the presence of muscle changes.
conclusionsMyosteatosis, whether alone or combined with sarcopenia, is highly prevalent in patients with cirrhosis and is associated with significantly worse outcomes. The prognostic role of sarcopenia should always be evaluated in relation to the presence of myosteatosis. IMPACT AND IMPLICATIONS: This study investigates the prognostic role of muscle changes in patients with cirrhosis. The novelty of this study is its multicentre, prospective nature and the fact that it distinguishes between the impact of individual muscle changes and their combination on prognosis in cirrhosis. This study highlights the prognostic role of myosteatosis, especially when combined with sarcopenia. On the other hand, the relevance of sarcopenia could be mitigated when considered together with myosteatosis. The implication from these findings is that sarcopenia should never be evaluated individually and that myosteatosis may play a dominant role in the prognosis of patients with cirrhosis.
Indexed as
Identifiers
38782120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.